E
Edo Vellenga
Researcher at University Medical Center Groningen
Publications - 370
Citations - 19968
Edo Vellenga is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Haematopoiesis & Stem cell. The author has an hindex of 72, co-authored 368 publications receiving 17974 citations. Previous affiliations of Edo Vellenga include Utrecht University & University of Groningen.
Papers
More filters
Journal ArticleDOI
High-dose daunorubicin in older patients with acute myeloid leukemia.
Bob Löwenberg,Gert J. Ossenkoppele,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Johan Maertens,Mojca Jongen-Lavrencic,Marie von Lilienfeld-Toal,Bart J. Biemond,Edo Vellenga,Marinus van Marwijk Kooy,Leo F. Verdonck,Joachim Beck,Hartmut Döhner,Alois Gratwohl,Thomas Pabst,Gregor Verhoef +18 more
TL;DR: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional doses, without additional toxic effects.
Journal ArticleDOI
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld,Ingo G.H. Schmidt-Wolf,Bronno van der Holt,Laila el Jarari,Uta Bertsch,Hans Salwender,Sonja Zweegman,Edo Vellenga,Annemiek Broyl,Igor Wolfgang Blau,Katja Weisel,Shulamiet Wittebol,Gerard M. J. Bos,Marian Stevens-Kroef,Christof Scheid,Michael Pfreundschuh,Dirk Hose,Anna Jauch,Helgi Van Der Velde,Reinier Raymakers,Martijn R. Schaafsma,Marie-Jose Kersten,Marinus van Marwijk-Kooy,Ulrich Duehrsen,Walter Lindemann,Pierre W. Wijermans,Henk M. Lokhorst,Hartmut Goldschmidt +27 more
TL;DR: Bortezomib during induction and maintenance improves CR and achieves superior PFS and OS and a benefit was also observed in patients with deletion 17p13.
Journal ArticleDOI
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
Hagop M. Kantarjian,Neil P. Shah,Jorge E. Cortes,Michele Baccarani,Mohan B. Agarwal,Maria Soledad Undurraga,Jianxiang Wang,Juan Julio Kassack Ipiña,Dong-Wook Kim,Michinori Ogura,Carolina Pavlovsky,Christian Junghanss,Jorge Milone,Franck E. Nicolini,Tadeusz Robak,Jan Van Droogenbroeck,Edo Vellenga,M. Brigid Bradley-Garelik,Chao Zhu,Andreas Hochhaus +19 more
TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
Journal ArticleDOI
Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse
Dimitri Breems,Wim L.J. van Putten,Peter C. Huijgens,Gert J. Ossenkoppele,Gregor Verhoef,Leo F. Verdonck,Edo Vellenga,Georgine E. de Greef,Emanuel Jacky,Johannes Van der Lelie,Marc Boogaerts,Bob Löwenberg +11 more
TL;DR: The prognostic index estimates the outcome of AML patients in first relapse using four commonly applied clinical parameters and might identify patients who are candidates for salvage and investigational therapy.
Journal ArticleDOI
Cytarabine dose for acute myeloid leukemia.
Bob Löwenberg,Thomas Pabst,Edo Vellenga,Wim L.J. van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Bart J. Biemond,Alois Gratwohl,Georgine E. de Greef,Leo F. Verdonck,Martijn R. Schaafsma,Michael Gregor,Matthias Theobald,Urs Schanz,Johan Maertens,Gert J. Ossenkoppele +17 more
TL;DR: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level.